A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Completed · Phase 1

Conditions studied: Suspected or Documented Gram-negative Bacterial Infection

In brief

This study aims to obtain plasma pharmacokinetic (PK) data and characterize the PK profile of imipenem (IMI), cilastatin (CIL), and relebactam (REL) following administration of a single intravenous (IV) dose of MK-7655A (a fixed ratio combination of imipenem/cilastatin/relebactam), hereafter referred to as IMI/REL.

Key facts

Study ID: NCT03230916
Run by: Merck Sharp & Dohme LLC
People needed: 47
Starts: 2017-11-06
Expected to finish: 2020-08-11
Last updated by the study team: 2024-02-06

Who can join

Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Has a parent or legally acceptable representative (LAR) who provides written informed consent for the trial on the participant's behalf.
Aged from birth to <18 years old.
Is hospitalized, currently receiving antibacterial treatment for confirmed or suspected Gram-negative bacterial infection, and expected to require hospitalization until at least 24 hours after completion of study drug administration.
Is not of reproductive potential; but if of reproductive potential, agrees to avoid becoming pregnant or impregnating a partner from the time of consent through 24 hours after completion of study drug administration.
Has clinically stable renal function at the time of screening that is judged to be within acceptable ranges.
Has sufficient intravascular access to receive study drug through an existing peripheral or central line.

You may not qualify if…

Has a personal history of hypersensitivity to imipenem/cilastatin (IMI) or to any of the following: any carbapenem, cephalosporin, penicillin, or other β-lactam agent; or other β-lactamase inhibitors (BLIs) e.g. tazobactam, sulbactam, clavulanic acid, avibactam.
Female is currently pregnant or breast feeding or has a positive serum β-human chorionic gonadotropin (β-hCG) pregnancy test.
Has a history of a seizure disorder requiring ongoing treatment with anti-convulsive therapy or prior treatment with anti-convulsive therapy within the last 3 years.
Has used or plans to use valproic acid or divalproex sodium within 2 weeks prior to screening or at any point between screening and 24 hours after the completion of study drug infusion.
Has received treatment or plans to receive treatment with any carbapenem antibiotic within 48 hours prior to initiation of study drug infusion or at any point between administration of study drug and the last PK sample collection.
Has used or plans to use any of the following medications, which are organic anion transporter (OAT) 1 or OAT3 inhibitors, within 1 week prior to screening or at any point between screening and the last PK sample collection: cimetidine, probenecid, indomethacin, mefenamic acid, furosemide or other loop diuretics (eg, bumetanide, torsemide, ethacrynic acid), angiotensin receptor blockers (eg, valsartan), and ketorolac.
Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 30 days prior to screening.
Has enrolled previously in the current trial and been discontinued, or has received REL for any other reason.
Has a current diagnosis of cystic fibrosis, meningitis, or severe sepsis.
Is expected to survive less than 72 hours after completion of study drug administration.
Has a history of clinically significant renal, hepatic, or hemodynamic instability.
Plans to use cardiopulmonary bypass, extracorporeal membrane oxygenation, hemodialysis, or peritoneal dialysis during the study.
For participants that are 2 to 17 years of age only: weighs outside of the 5th to 95th percentile based on age.
Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.
Has a planned blood transfusion within 24 hours of study drug administration or expected before the end of the PK sampling.
Has had significant blood loss (≥5% of total blood volume) within 4 weeks before the screening visit.

Where it is running

Arkansas Children's Hospital ( Site 1311) — Little Rock, Arkansas, United States
Children's Hospital of Orange County ( Site 1301) — Orange, California, United States
Rady Children's Hospital-San Diego ( Site 1305) — San Diego, California, United States
Our Lady of the Lake Hospital ( Site 1304) — Baton Rouge, Louisiana, United States
St. Louis Children's Hospital ( Site 1322) — St Louis, Missouri, United States
Duke University Medical Center ( Site 1317) — Durham, North Carolina, United States
The Children's Hospital of Philadelphia ( Site 1318) — Philadelphia, Pennsylvania, United States
Seattle Childrens Hospital ( Site 1321) — Seattle, Washington, United States
MHAT Pazardjik AD ( Site 0208) — Pazardzhik, Pazardzhik, Bulgaria
UMHAT Deva Maria. EOOD ( Site 0209) — Burgas, Bulgaria
UMHAT Dr. Georgi Stranski EAD ( Site 0211) — Pleven, Bulgaria
UMHAT Kanev AD ( Site 0203) — Rousse, Bulgaria
UMHAT Kanev AD ( Site 0212) — Rousse, Bulgaria
Hospital Pablo Tobon Uribe ( Site 0301) — Medellín, Antioquia, Colombia
Hospital General de Medellin Luz Castro de Gutierrez ( Site 0303) — Medellín, Antioquia, Colombia
Fundacion Valle del Lili ( Site 0300) — Cali, Valle del Cauca Department, Colombia
General Hospital of Thessaloniki Hippokrateio ( Site 1402) — Thessaloniki, Greece
Akershus Universitetssykehus HF ( Site 0903) — Loerenskog, Akershus, Norway
Stavanger Universitetssykehus, Helse Stavanger ( Site 0901) — Stavanger, Rogaland, Norway
St. Olavs Hospital ( Site 0900) — Trondheim, Sor-Trondelag, Norway
Haukeland Universitetssjukehus ( Site 0902) — Bergen, Vestfold, Norway
SPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 1002) — Łomianki, Masovian Voivodeship, Poland
Wojewodzki Specjalistyczny Szpital im. Bieganskiego w Lodzi ( Site 1000) — Lodz, Łódź Voivodeship, Poland
SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 1214) — Dnipro, Dnipropetrovsk Oblast, Ukraine
Kharkiv City Children Hospital 16 ( Site 1200) — Kharkiv, Kharkiv Oblast, Ukraine

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.